Dottikon ES Holding AG (SWX: DESN)
Health Care · Pharmaceuticals · CH
CHF275.50
-0.18% today · -5.3% 1Y
Dottikon ES Holding AG (SWX: DESN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $4.75B and employs 900 people.
Over the last twelve months the share price has lost 5.3%, trading between 259.00 and 396.00.
Tweenvest scores Dottikon ES Holding AG across four factors: quality 83/100, value 70/100, growth 81/100. Its strongest factor is quality.
DESN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.75B
- Revenue (TTM)
- $548.45M
- P/E
- 36.83
- EPS
- 7.49
- Dividend yield
- —
- Beta (5Y)
- 0.99
- 52-week high
- CHF396.00
- 52-week low
- CHF259.00
- Avg volume (3M)
- —
- Shares outstanding
- 13.82M
- Employees
- 900
- Next earnings
- —
About Dottikon ES Holding AG
Dottikon ES Holding AG manufactures and sells performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical maceutic industries in Europe, Switzerland, the United States, and Asia. The company’s chemicals and intermediates include amines, anilines, azaindoles, benzimidazoles, benzoic acid derivatives, benzyl compounds, boron building blocks, chiral compounds, cyclohexane derivatives, cyclopropyl building blocks, indazoles, indoles, N-heterocycles, nitrate esters, nitroaromatic compounds, O-heterocycles, phenols and anisoles, and pyridine building blocks. It also offers Dottisol, an isosorbide dimethyl ether for application as a solubility enhancer in cosmetic, pharma, and agro products, as well as a performance additive in various industries. In addition, the company is involved in recycling and waste treatment which includes the recycling, thermal recovery, and high-temperature incineration of waste streams, as well as wastewater treatment and purification activities. Further, it offers chemical custom manufacturing, nitrosamine risk assessment, and containment services; and performance chemicals, including aromatic and alicyclic diamines, bio-based organosilanes, and phlegmatized azides. The company was founded in 1913 and is headquartered in Dottikon, Switzerland. Dottikon ES Holding AG is a subsidiary of EVOLMA Holding AG.
- ISIN
- CH0582581713
- Founded
- 1913
- Listed since
- Nov 3, 2003
- Exchange
- SIX Swiss Exchange
- Currency
- CHF
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,211.05 | -1.83% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $271.68 | -0.53% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $154.97 | -0.95% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.20 | -1.50% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.46 | -1.84% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.29 | -1.00% |
Figures last refreshed Aug 18, 2026.